Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Citius Pharmaceuticals Inc
Nieuws
Citius Pharmaceuticals Inc
CTXR
NAS
: CTXR
| ISIN: US17322U2078
26/04/2024
0,665 USD
(-9,25%)
(-9,25%)
26/04/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
26 april 2024 ·
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
· Persbericht
11 april 2024 ·
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
· Persbericht
4 april 2024 ·
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
· Persbericht
18 maart 2024 ·
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
· Persbericht
7 maart 2024 ·
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
· Persbericht
26 februari 2024 ·
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
· Persbericht
23 februari 2024 ·
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
· Persbericht
14 februari 2024 ·
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
· Persbericht
14 februari 2024 ·
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
· Persbericht
23 januari 2024 ·
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
· Persbericht
2 januari 2024 ·
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
· Persbericht
2 januari 2024 ·
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
· Persbericht
9 november 2023 ·
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
· Persbericht
31 oktober 2023 ·
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
· Persbericht
24 oktober 2023 ·
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
· Persbericht
18 september 2023 ·
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
· Persbericht
13 september 2023 ·
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
· Persbericht
8 september 2023 ·
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™
· Persbericht
6 september 2023 ·
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
· Persbericht
14 augustus 2023 ·
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe